Latest News about ROIV
Recent news which mentions ROIV
From Benzinga
From Benzinga
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
May 16, 2023
Tickers
ROIV
From Benzinga
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
April 23, 2023
From Motley Fool
From Motley Fool
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
April 17, 2023
From Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
April 17, 2023
From Motley Fool
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
April 17, 2023
From Benzinga
From InvestorPlace
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 21, 2023
From Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
March 15, 2023
Tickers
ROIV
From Benzinga
From InvestorPlace
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
From Benzinga
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
February 14, 2023
From Benzinga
Earnings Scheduled For February 13, 2023
February 13, 2023
From Benzinga
From Benzinga
From Benzinga
Why Roivant Sciences' Shares Are Up Thursday
December 01, 2022
From Motley Fool
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
November 15, 2022
From Benzinga
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
November 15, 2022
From Benzinga
Earnings Scheduled For November 14, 2022
November 14, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 08, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.